Biotech company Vaxart posted mixed phase 1 results for its tablet-based Covid-19 vaccine, causing its stock to decline by over 60% from last week's high. Although the vaccine was well tolerated and produced multiple immune responses, it failed to induce neutralizing antibodies in most subjects...
Biotech company Vaxart posted mixed phase 1 results for its tablet-based Covid-19 vaccine, causing its stock to decline by over 60% from last week's high. Although the vaccine was well tolerated and produced multiple immune responses, it failed to induce neutralizing antibodies in most subjects...
Share this Article
Recommended